Logo image of ACAD

ACADIA PHARMACEUTICALS INC (ACAD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ACAD - US0042251084 - Common Stock

26.86 USD
+0.4 (+1.51%)
Last: 1/14/2026, 8:09:45 PM
26.83 USD
-0.03 (-0.11%)
After Hours: 1/14/2026, 8:09:45 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to ACAD. ACAD was compared to 528 industry peers in the Biotechnology industry. ACAD has an excellent financial health rating, but there are some minor concerns on its profitability. ACAD has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year ACAD was profitable.
  • In the past year ACAD had a positive cash flow from operations.
  • In the past 5 years ACAD always reported negative net income.
  • In the past 5 years ACAD always reported negative operating cash flow.
ACAD Yearly Net Income VS EBIT VS OCF VS FCFACAD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

  • ACAD has a better Return On Assets (19.63%) than 96.97% of its industry peers.
  • Looking at the Return On Equity, with a value of 28.47%, ACAD belongs to the top of the industry, outperforming 97.54% of the companies in the same industry.
  • The Return On Invested Capital of ACAD (7.66%) is better than 93.75% of its industry peers.
Industry RankSector Rank
ROA 19.63%
ROE 28.47%
ROIC 7.66%
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
ACAD Yearly ROA, ROE, ROICACAD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • The Profit Margin of ACAD (24.94%) is better than 94.89% of its industry peers.
  • ACAD has a Operating Margin of 9.02%. This is amongst the best in the industry. ACAD outperforms 91.10% of its industry peers.
  • Looking at the Gross Margin, with a value of 91.92%, ACAD belongs to the top of the industry, outperforming 93.18% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ACAD has grown nicely.
Industry RankSector Rank
OM 9.02%
PM (TTM) 24.94%
GM 91.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
ACAD Yearly Profit, Operating, Gross MarginsACAD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

7

2. Health

2.1 Basic Checks

  • ACAD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for ACAD has been increased compared to 1 year ago.
  • The number of shares outstanding for ACAD has been increased compared to 5 years ago.
  • There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACAD Yearly Shares OutstandingACAD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ACAD Yearly Total Debt VS Total AssetsACAD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • ACAD has an Altman-Z score of 5.97. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 5.97, ACAD is doing good in the industry, outperforming 75.76% of the companies in the same industry.
  • ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.97
ROIC/WACC0.87
WACC8.82%
ACAD Yearly LT Debt VS Equity VS FCFACAD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 3.02 indicates that ACAD has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 3.02, ACAD is doing worse than 63.83% of the companies in the same industry.
  • A Quick Ratio of 2.94 indicates that ACAD has no problem at all paying its short term obligations.
  • ACAD's Quick ratio of 2.94 is on the low side compared to the rest of the industry. ACAD is outperformed by 62.50% of its industry peers.
Industry RankSector Rank
Current Ratio 3.02
Quick Ratio 2.94
ACAD Yearly Current Assets VS Current LiabilitesACAD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

  • The earnings per share for ACAD have decreased strongly by -14.10% in the last year.
  • ACAD shows a strong growth in Revenue. In the last year, the Revenue has grown by 121.75%.
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%

3.2 Future

  • ACAD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.40% yearly.
  • The Revenue is expected to grow by 10.47% on average over the next years. This is quite good.
EPS Next Y71.6%
EPS Next 2Y29.52%
EPS Next 3Y35.28%
EPS Next 5Y39.4%
Revenue Next Year11.07%
Revenue Next 2Y11.29%
Revenue Next 3Y11.08%
Revenue Next 5Y10.47%

3.3 Evolution

ACAD Yearly Revenue VS EstimatesACAD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 500M 1B 1.5B 2B
ACAD Yearly EPS VS EstimatesACAD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 40.09, which means the current valuation is very expensive for ACAD.
  • Based on the Price/Earnings ratio, ACAD is valued cheaply inside the industry as 91.67% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 27.33, ACAD is valued a bit more expensive.
  • A Price/Forward Earnings ratio of 33.36 indicates a quite expensive valuation of ACAD.
  • Based on the Price/Forward Earnings ratio, ACAD is valued cheaper than 92.05% of the companies in the same industry.
  • ACAD's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 24.12.
Industry RankSector Rank
PE 40.09
Fwd PE 33.36
ACAD Price Earnings VS Forward Price EarningsACAD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ACAD is valued cheaply inside the industry as 92.80% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ACAD indicates a rather cheap valuation: ACAD is cheaper than 95.27% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 20.87
EV/EBITDA 28.03
ACAD Per share dataACAD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • ACAD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of ACAD may justify a higher PE ratio.
  • ACAD's earnings are expected to grow with 35.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.56
PEG (5Y)N/A
EPS Next 2Y29.52%
EPS Next 3Y35.28%

More info and screens

0

5. Dividend

5.1 Amount

  • ACAD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ACADIA PHARMACEUTICALS INC

NASDAQ:ACAD (1/14/2026, 8:09:45 PM)

After market: 26.83 -0.03 (-0.11%)

26.86

+0.4 (+1.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)02-24
Inst Owners101.21%
Inst Owner Change-0.03%
Ins Owners0.26%
Ins Owner Change-3.63%
Market Cap4.54B
Revenue(TTM)1.05B
Net Income(TTM)261.17M
Analysts76.92
Price Target29.96 (11.54%)
Short Float %5.18%
Short Ratio5.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.34%
Min EPS beat(2)14.46%
Max EPS beat(2)178.22%
EPS beat(4)2
Avg EPS beat(4)20.1%
Min EPS beat(4)-109.07%
Max EPS beat(4)178.22%
EPS beat(8)5
Avg EPS beat(8)29%
EPS beat(12)7
Avg EPS beat(12)26.97%
EPS beat(16)10
Avg EPS beat(16)24.21%
Revenue beat(2)0
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-1.19%
Max Revenue beat(2)-0.93%
Revenue beat(4)1
Avg Revenue beat(4)-2.59%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.08%
Revenue beat(8)3
Avg Revenue beat(8)-1.62%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)6
Avg Revenue beat(16)-1.45%
PT rev (1m)0.36%
PT rev (3m)1.08%
EPS NQ rev (1m)-0.35%
EPS NQ rev (3m)5.79%
EPS NY rev (1m)-1.14%
EPS NY rev (3m)43.73%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)2.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.01%
Valuation
Industry RankSector Rank
PE 40.09
Fwd PE 33.36
P/S 4.34
P/FCF 20.87
P/OCF 14.3
P/B 4.95
P/tB 5.64
EV/EBITDA 28.03
EPS(TTM)0.67
EY2.49%
EPS(NY)0.81
Fwd EY3%
FCF(TTM)1.29
FCFY4.79%
OCF(TTM)1.88
OCFY6.99%
SpS6.19
BVpS5.42
TBVpS4.76
PEG (NY)0.56
PEG (5Y)N/A
Graham Number9.04
Profitability
Industry RankSector Rank
ROA 19.63%
ROE 28.47%
ROCE 9.69%
ROIC 7.66%
ROICexc 58.65%
ROICexgc 479.54%
OM 9.02%
PM (TTM) 24.94%
GM 91.92%
FCFM 20.79%
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
F-Score4
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 711.57%
Cap/Sales 9.55%
Interest Coverage 250
Cash Conversion 292.92%
Profit Quality 83.36%
Current Ratio 3.02
Quick Ratio 2.94
Altman-Z 5.97
F-Score4
WACC8.82%
ROIC/WACC0.87
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)567.7%
Cap/Sales(5y)341.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
EPS Next Y71.6%
EPS Next 2Y29.52%
EPS Next 3Y35.28%
EPS Next 5Y39.4%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
Revenue Next Year11.07%
Revenue Next 2Y11.29%
Revenue Next 3Y11.08%
Revenue Next 5Y10.47%
EBIT growth 1Y50.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.82%
EBIT Next 3Y27.27%
EBIT Next 5Y43.9%
FCF growth 1Y264.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y443.26%
OCF growth 3YN/A
OCF growth 5YN/A

ACADIA PHARMACEUTICALS INC / ACAD FAQ

What is the fundamental rating for ACAD stock?

ChartMill assigns a fundamental rating of 5 / 10 to ACAD.


What is the valuation status of ACADIA PHARMACEUTICALS INC (ACAD) stock?

ChartMill assigns a valuation rating of 6 / 10 to ACADIA PHARMACEUTICALS INC (ACAD). This can be considered as Fairly Valued.


Can you provide the profitability details for ACADIA PHARMACEUTICALS INC?

ACADIA PHARMACEUTICALS INC (ACAD) has a profitability rating of 6 / 10.


What are the PE and PB ratios of ACADIA PHARMACEUTICALS INC (ACAD) stock?

The Price/Earnings (PE) ratio for ACADIA PHARMACEUTICALS INC (ACAD) is 40.09 and the Price/Book (PB) ratio is 4.95.


Can you provide the financial health for ACAD stock?

The financial health rating of ACADIA PHARMACEUTICALS INC (ACAD) is 7 / 10.